DAPA-CKD 试验基线特征:达格列净在慢性肾脏病中的研究人群
DAPA-CKD 试验纳入 4304 例 UACR≥200 mg/g 且 eGFR 25–75 mL/min/1.73 m² 的 CKD 患者,随机接受达格列净 10 mg 每日一次或安慰剂。基线平均 eGFR 43.1 mL/min/1.73 m²,中位 UACR 949 mg/g,68% 合并 T2D,97% 使用 ACEI/ARB。研究旨在评估达格列净在伴或不伴 T2D 的 CKD 2–4 期患者中的疗效与安全性。
要点
- DAPA-CKD 纳入伴或不伴 T2D 的 CKD 患者,病因包括糖尿病、缺血/高血压肾病和慢性肾小球肾炎。
- 基线平均 eGFR 43.1 mL/min/1.73 m²,中位 UACR 949 mg/g,97% 使用 ACEI/ARB。
- 与 CREDENCE 相比,DAPA-CKD 平均 eGFR 低 13.1 mL/min/1.73 m²,且纳入非糖尿病病因 CKD。
核心结论
- DAPA-CKD 试验纳入多种病因 CKD 且接受 RAS 阻断治疗的患者,将评估达格列净在 CKD 2–4 期伴白蛋白尿患者中的疗效与安全性。
研究设计与样本
- DAPA-CKD(NCT03036150)为随机对照试验,4304 例 UACR≥200 mg/g 且 eGFR 25–75 mL/min/1.73 m² 的 CKD 患者随机接受达格列净 10 mg 每日一次或安慰剂。
主要发现
- 基线平均 eGFR 为 43.1 mL/min/1.73 m²,中位 UACR 为 949 mg/g(108 mg/mmol)。
- 2906 例(68%)诊断为 T2D,其中 396 例 CKD 病因为非糖尿病。
- CKD 病因中糖尿病 2510 例,缺血/高血压肾病 687 例,慢性肾小球肾炎 695 例(其中 IgA 肾病 270 例)。
- 4174 例(97%)使用 ACEI 或 ARB,1882 例(43.7%)使用利尿剂,229 例(5.3%)使用 MRA,122 例(2.8%)使用 GLP-1 受体激动剂。
- DAPA-CKD 平均 eGFR 较 CREDENCE 低 13.1 mL/min/1.73 m²,与 FIDELIO-DKD 和 SONAR 相似。
临床怎么用
- DAPA-CKD 基线特征提示达格列净研究人群覆盖伴和不伴 T2D 的 CKD 2–4 期伴白蛋白尿患者,且多数已接受 ACEI/ARB 治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. METHODS: In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Mean eGFR was 43.1 mL/min/1.73 m2 and median UACR was 949 mg/g (108 mg/mmol). RESULTS: Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1 mL/min/1.73 m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). CONCLUSIONS: Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D.
引用
- Wheeler DC, Stefansson BV, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020. PMID: 32862232. doi:10.1093/ndt/gfaa234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。